Share on StockTwits

Investment analysts at Cowen and Company assumed coverage on shares of Loxo Oncology (NASDAQ:LOXO) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Analysts at Stifel Nicolaus initiated coverage on shares of Loxo Oncology in a research note on Tuesday. They set a “buy” rating and a $20.00 price target on the stock. Analysts at JMP Securities initiated coverage on shares of Loxo Oncology in a research note on Tuesday, August 26th. They set an “outperform” rating and a $23.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $20.75.

Loxo Oncology (NASDAQ:LOXO) traded up 1.31% on Tuesday, hitting $13.18. 44,889 shares of the company’s stock traded hands. Loxo Oncology has a one year low of $12.687 and a one year high of $13.42. The stock’s 50-day moving average is $13.03 and its 200-day moving average is $13.03. The company’s market cap is $210.1 million.

Loxo Oncology, Inc (NASDAQ:LOXO) develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.